Precose
(Acarbose)ApprovedSmall molecule
BayerAcarbose is used to help control blood sugar levels in people with type 2 diabetes by slowing down the digestion of carbohydrates so sugar enters the bloodstream more slowly.[2] Precose is currently approved and in use across 15 indications[4].[1]
Precose is one of 393 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
15
Indications
75
Total Trials
2
Active Trials
392
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 15 indications
Competition
Competitive Landscape
176 competitors in Obesity
#DrugCompanyPhaseTrials
1Precose
BayerApproved
Decadron
AAspen Global Incorporated
Phase 3
Maridebart Cafraglutide
AmgenPhase 3
HRS9531
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Zenagamtide
Novo NordiskPhase 3
Cagrisema
Novo NordiskPhase 3
Ribupatide
KKailera
Phase 3
Aleniglipron
GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
Semaglutide or Tirzepatide
NNational and Kapodistrian University of Athens
Phase 3
Actemra
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes17 trials
Show 14 more trials
Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.
Completed·—·Phase 2·NCT01839344·19 enrolled
Type 2 Diabetes Mellitus7 trials
Metformin5 trials
Oral4 trials
37 more indications
Polycystic Ovary Syndrome2 trials
CAR2 trials
Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients
Completed·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 4·NCT02355509·21 enrolled
Monotherapy1 trial
Type 2 Diabetic Patients1 trial
Endothelial Function1 trial
Coronary Artery Disease1 trial
Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial)
Unknown status·—·Phase 4·NCT00858676·150 enrolled
Oxidative Stress1 trial
Hyperinsulinemic Hypoglycemia1 trial
Real-world Study1 trial
Coronary Atherosclerosis1 trial
Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
Unknown status·—·Phase 4·NCT03602638·300 enrolled
Insulin Secretion1 trial
Vascular Disease1 trial
Overweight1 trial
Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.
Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·N/A·NCT03961659·87 enrolled
Non-Alcoholic Fatty Liver Disease1 trial
Gestational Diabetes1 trial
Dyslipidemia1 trial
Cardiovascular Disease1 trial
Effectiveness1 trial
Renal Cell Carcinoma1 trial
Prevention1 trial
Acarbose and Secondary Prevention After Coronary Stenting
Completed·TTranslational Research Center for Medical Innovation, Kobe, Hyogo, Japan·Phase 3·NCT00221156·300 enrolled
Safety and Efficacy1 trial
Chronic Hepatitis1 trial
Impaired glucose tolerance1 trial
Aging1 trial
Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT02865499·8 enrolled
Regulatory
FDA Approval Timeline[5]
May 29, 1997
PRECOSE
NDA NDA020482
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Precose drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Acarbose. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]